Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000947871-16-001330
Filing Date
2016-07-08
Accepted
2016-07-08 16:12:15
Documents
2
Group Members
ORBIMED CAPITAL GP V LLCSAMUEL D. ISALY

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss1844_sc13ga.htm SC 13G/A 119530
2 JOINT FILING AGREEMENT ss1844_ex99a.htm EX-99.A 19951
  Complete submission text file 0000947871-16-001330.txt   140988
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13G/A

Mailing Address 828 RICHMOND STREET WEST TORONTO A6 M6J 1C9
Business Address 828 RICHMOND STREET WEST TORONTO A6 M6J 1C9 416-703-2449
Cynapsus Therapeutics Inc. (Subject) CIK: 0001532079 (see all company filings)

EIN.: 981226819 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88902 | Film No.: 161759578
SIC: 2834 Pharmaceutical Preparations